cGMP-dependent protein kinase modulators.
The first cGMP-dependent protein kinase (PKG) modulators were described nearly 30 years ago and since then more than 200 compounds have been synthesized and tested, but only a small subset of these compounds has found widespread application. The aim of this review is to suggest a framework for evaluating and using PKG activators and inhibitors and to explore and interpret PKG signal transduction in cell culture-based model systems. Therefore, cross-reactivity of cGMP-analogs with other classes of cyclic nucleotide binding proteins, as well as the advantages and problems of newly designed PKG inhibitors, are discussed. Additional information and a search option are available at www.cyclic-nucleotides.org
Butt
Elke
E
Institute of Clinical Biochemistry, University of Wuerzburg, Grombuehlstrasse 12, Wuerzburg, 97080, Germany. butt@klin-biochem.uni-wuerzburg.de
D000818:Animals; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000031:analogs & derivatives; D017869:Cyclic GMP-Dependent Protein Kinases / Q000187:drug effects* / Q000378:metabolism; D020536:Enzyme Activators / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D034741:RNA, Small Interfering / Q000378:metabolism; D015398:Signal Transduction
D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D034741:RNA, Small Interfering; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP